Immunohistochemistry (IHC): Increase the Success of Biomarker Integration in Clinical Development

“With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, you can increase the success of biomarker integration in clinical development.”

– Amanda Finan, PhD, Head IHC/Histology R&D and Clinical Validations at Cerba Research

Next Generation Biomarker Discovery

Strong & Sustainable Partnership

Learn how Cerba Research and Fulgent are enhancing genomic data in clinical trials for better patient outcomes across all phases through their NGS services. In this presentation, you’ll learn how we’re accelerating precision medicine with next generation biomarker discovery through our partnership and specific expertise in oncology, rare disease, CNS, metabolic, and infectious diseases.

A Biomarker Journey in Immuno-Oncology Utilizing Immunohistochemistry

In immuno-oncology (IO) research, biomarkers present the opportunity to identify and target the patient response to a potential new therapeutic, but how can it be integrated into a clinical development plan to increase the effectiveness of clinical trials?

With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, sponsors will increase the success of biomarker integration in their clinical trials. 

Watch our webinar now!

Non-Invasive Novel Biomarkers to Predict Alzheimer’s Risk

Two Platforms for Next Generation Biomarker Discovery